Human Gut Microbiota and Gastrointestinal Cancer

Genomics, Proteomics and Bioinformatics

Volumn 16, Issue 1, 2018, Pages 33-49

  Meng, Changting ^a,b   Bai, Chunmei ^b   Brown, Thomas D ^c   Hood, Leroy E ^a,c   Tian, Qiang ^a,d  

^a INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c SWEDISH MEDICAL CENTER   (United States)

^d P4 Medicine Institute   (United States)

Author keywords

Carcinogenesis; Immune regulation; Inflammation; Microbial metabolites; Traditional Chinese Medicine

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BAICALEIN; BAICALIN; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; HERBACEOUS AGENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IRINOTECAN; PHY 906; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT; TUMOR MARKER; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; CHINESE MEDICINE; CHRONIC INFLAMMATION; COLORECTAL CANCER; DIET; DIGESTIVE SYSTEM CANCER; DYSBIOSIS; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGUS CANCER; FUTUROLOGY; GENOMIC INSTABILITY; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; INTESTINE FLORA; LIVER CANCER; META ANALYSIS (TOPIC); METABOLITE; NONHUMAN; OBESITY; PANCREAS CANCER; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; STOMACH CANCER; SYSTEMATIC REVIEW (TOPIC); DRUG EFFECT; GASTROINTESTINAL TRACT; GASTROINTESTINAL TUMOR; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL TRACT; HUMANS;

EID: 85042613567     PISSN: 16720229     EISSN: 22103244     Source Type: Journal    
DOI: 10.1016/j.gpb.2017.06.002     Document Type: Review

References (244)

1. Pisani, P., Parkin, D.M., Muñoz, N., Ferlay, J., Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 6 (1997), 387–400.
2. de Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray, F., Forman, D., et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13 (2012), 607–615.
3. Parkin, D.M., The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118 (2006), 3030–3044.
4. Plummer, M., de Martel, C., Vignat, J., Ferlay, J., Bray, F., Franceschi, S., Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 4 (2016), e609–e616.
5. Garrett, W.S., Cancer and the microbiota. Science 348 (2015), 80–86.
6. Gill, S.R., Pop, M., Deboy, R.T., Eckburg, P.B., Turnbaugh, P.J., Samuel, B.S., et al. Metagenomic analysis of the human distal gut microbiome. Science 312 (2006), 1355–1359.
7. Hamm, A.K., Weir, T.L., Editorial on “cancer and the microbiota” published in science. Ann Transl Med, 3, 2015, 175.
8. Ericsson, A.C., Akter, S., Hanson, M.M., Busi, S.B., Parker, T.W., Schehr, R.J., et al. Differential susceptibility to colorectal cancer due to naturally occurring gut microbiota. Oncotarget 6 (2015), 33689–33704.
9. Hiergeist, A., Gläsner, J., Reischl, U., Gessner, A., Analyses of intestinal microbiota: culture versus sequencing. ILAR J 56 (2015), 228–240.
10. Olsen, G.J., Lane, D.J., Giovannoni, S.J., Pace, N.R., Stahl, D.A., Microbial ecology and evolution: a ribosomal RNA approach. Annu Rev Microbiol 40 (1986), 337–365.
11. Tebani, A., Afonso, C., Marret, S., Bekri, S., Omics-based strategies in precision medicine: toward a paradigm shift in inborn errors of metabolism investigations. Int J Mol Sci, 17, 2016, E1555.
12. Kuleshov, V., Jiang, C., Zhou, W., Jahanbani, F., Batzoglou, S., Snyder, M., Synthetic long-read sequencing reveals intraspecies diversity in the human microbiome. Nat Biotechnol 34 (2016), 64–69.
13. Eckburg, P.B., Bik, E.M., Bernstein, C.N., Purdom, E., Dethlefsen, L., Sargent, M., et al. Diversity of the human intestinal microbial flora. Science 308 (2005), 1635–1638.
14. Hattori, N., Ushijima, T., Epigenetic impact of infection on carcinogenesis: mechanisms and applications. Genome Med, 8, 2016, 10.
15. Klampfer, L., Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets 11 (2011), 451–464.
16. Putoczki, T.L., Thiem, S., Loving, A., Busuttil, R.A., Wilson, N.J., Ziegler, P.K., et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 24 (2013), 257–271.
17. Shitashige, M., Satow, R., Honda, K., Ono, M., Hirohashi, S., Yamada, T., Regulation of Wnt signaling by the nuclear pore complex. Gastroenterology 134 (2008), 1961–1971 1971.e1−4.
18. Shitashige, M., Hirohashi, S., Yamada, T., Wnt signaling inside the nucleus. Cancer Sci 99 (2008), 631–637.
19. Hussain, S.P., Amstad, P., Raja, K., Ambs, S., Nagashima, M., Bennett, W.P., et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60 (2000), 3333–3337.
20. Raponi, M., Winkler, H., Dracopoli, N.C., KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 8 (2008), 413–418.
21. Gensollen, T., Iyer, S.S., Kasper, D.L., Blumberg, R.S., How colonization by microbiota in early life shapes the immune system. Science 352 (2016), 539–544.
22. Palm, N.W., de Zoete, M.R., Flavell, R.A., Immune-microbiota interactions in health and disease. Clin Immunol 159 (2015), 122–127.
23. Vijay-Kumar, M., Gewirtz, A.T., Flagellin: key target of mucosal innate immunity. Mucosal Immunol 2 (2009), 197–205.
24. Hayashi, F., Smith, K.D., Ozinsky, A., Hawn, T.R., Yi, E.C., Goodlett, D.R., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410 (2001), 1099–1103.
25. Brown, D.G., Rao, S., Weir, T.L., O'Malia, J., Bazan, M., Brown, R.J., et al. Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab, 4, 2016, 11.
26. Ginsburg, I., Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis 2 (2002), 171–179.
27. Hermann, C., Spreitzer, I., Schröder, N.W., Morath, S., Lehner, M.D., Fischer, W., et al. Cytokine induction by purified lipoteichoic acids from various bacterial species–role of LBP, sCD14, CD14 and failure to induce IL-12 and subsequent IFN-gamma release. Eur J Immunol 32 (2002), 541–551.
28. Carino, A., Graziosi, L., D'Amore, C., Cipriani, S., Marchianò S., Marino, E., et al. The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines. Oncotarget 7 (2016), 61021–61035.
29. Louis, P., Hold, G.L., Flint, H.J., The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 12 (2014), 661–672.
30. Saretzki, G., Cellular senescence in the development and treatment of cancer. Curr Pharm Des 16 (2010), 79–100.
31. Smith, P.M., Howitt, M.R., Panikov, N., Michaud, M., Gallini, C.A., Bohlooly-Y, M., et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341 (2013), 569–573.
32. Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.A., Nakato, G., Takahashi, D., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504 (2013), 446–450.
33. Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504 (2013), 451–455.
34. Doorakkers, E., Lagergren, J., Engstrand, L., Brusselaers, N., Eradication of Helicobacter pylori and gastric cancer: a systematic review and meta-analysis of cohort studies. J Natl Cancer Inst, 108, 2016, djw132.
35. Khatoon, J., Rai, R.P., Prasad, K.N., Role of Helicobacter pylori in gastric cancer: updates. World J Gastrointest Oncol 8 (2016), 147–158.
36. Odenbreit, S., Püls, J., Sedlmaier, B., Gerland, E., Fischer, W., Haas, R., Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 287 (2000), 1497–1500.
37. Kwok, T., Zabler, D., Urman, S., Rohde, M., Hartig, R., Wessler, S., et al. Helicobacter exploits integrin for type IV secretion and kinase activation. Nature 449 (2007), 862–866.
38. Moyat, M., Velin, D., Immune responses to Helicobacter pylori infection. World J Gastroenterol 20 (2014), 5583–5593.
39. Udhayakumar, G., Jayanthi, V., Devaraj, N., Devaraj, H., Interaction of MUC1 with beta-catenin modulates the Wnt target gene cyclinD1 in H. pylori-induced gastric cancer. Mol Carcinog 46 (2007), 807–817.
40. Yong, X., Tang, B., Li, B.S., Xie, R., Hu, C.J., Luo, G., et al. Helicobacter pylori virulence factor CagA promotes tumorigenesis of gastric cancer via multiple signaling pathways. Cell Commun Signal, 13, 2015, 30.
41. Hotchin, N.A., Cover, T.L., Akhtar, N., Cell vacuolation induced by the VacA cytotoxin of Helicobacter pylori is regulated by the Rac1 GTPase. J Biol Chem 275 (2000), 14009–14012.
42. Suzuki, J., Ohnsihi, H., Shibata, H., Wada, A., Hirayama, T., Iiri, T., et al. Dynamin is involved in human epithelial cell vacuolation caused by the Helicobacter pylori-produced cytotoxin VacA. J Clin Invest 107 (2001), 363–370.
43. Mashima, H., Suzuki, J., Hirayama, T., Yoshikumi, Y., Ohno, H., Ohnishi, H., et al. Involvement of vesicle-associated membrane protein 7 in human gastric epithelial cell vacuolation induced by Helicobacter pylori-produced VacA. Infect Immun 76 (2008), 2296–2303.
44. Yahiro, K., Akazawa, Y., Nakano, M., Suzuki, H., Hisatune, J., Isomoto, H., et al. Helicobacter pylori VacA induces apoptosis by accumulation of connexin 43 in autophagic vesicles via a Rac1/ERK-dependent pathway. Cell Death Discov, 1, 2015, 15035.
45. Ricci, V., Relationship between VacA toxin and host cell autophagy in Helicobacter pylori infection of the human stomach: a few answers, many questions. Toxins (Basel), 8, 2016, E203.
46. Galmiche, A., Rassow, J., Targeting of Helicobacter pylori VacA to mitochondria. Gut Microbes 1 (2010), 392–395.
47. Willhite, D.C., Blanke, S.R., Helicobacter pylori vacuolating cytotoxin enters cells, localizes to the mitochondria, and induces mitochondrial membrane permeability changes correlated to toxin channel activity. Cell Microbiol 6 (2004), 143–154.
48. Jain, P., Luo, Z.Q., Blanke, S.R., Helicobacter pylori vacuolating cytotoxin A (VacA) engages the mitochondrial fission machinery to induce host cell death. Proc Natl Acad Sci U S A 108 (2011), 16032–16037.
49. Ki, M.R., Lee, H.R., Goo, M.J., Hong, I.H., Do, S.H., Jeong, D.H., et al. Differential regulation of ERK1/2 and p38 MAP kinases in VacA-induced apoptosis of gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 294 (2008), G635–G647.
50. Caputo, R., Tuccillo, C., Manzo, B.A., Zarrilli, R., Tortora, G., CeV, Blanco, et al. Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism. Clin Cancer Res 9 (2003), 2015–2021.
51. Liu, N., Zhou, N., Chai, N., Liu, X., Jiang, H., Wu, Q., et al. Helicobacter pylori promotes angiogenesis depending on Wnt/beta-catenin-mediated vascular endothelial growth factor via the cyclooxygenase-2 pathway in gastric cancer. BMC Cancer, 16, 2016, 321.
52. Song, X., Xin, N., Wang, W., Zhao, C., Wnt/β-catenin, an oncogenic pathway targeted by H. pylori in gastric carcinogenesis. Oncotarget 6 (2015), 35579–35588.
53. Nakayama, M., Hisatsune, J., Yamasaki, E., Isomoto, H., Kurazono, H., Hatakeyama, M., et al. Helicobacter pylori VacA-induced inhibition of GSK3 through the PI3K/Akt signaling pathway. J Biol Chem 284 (2009), 1612–1619.
54. Sato, F., Meltzer, S.J., CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 106 (2006), 483–493.
55. Sitaraman, R., Helicobacter pylori DNA methyltransferases and the epigenetic field effect in cancerization. Front Microbiol, 5, 2014, 115.
56. De Witte, C., Schulz, C., Smet, A., Malfertheiner, P., Haesebrouck, F., Other Helicobacters and gastric microbiota. Helicobacter 21 (2016), 62–68.
57. Maldonado-Contreras, A., Goldfarb, K.C., Godoy-Vitorino, F., Karaoz, U., Contreras, M., Blaser, M.J., et al. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME J 5 (2011), 574–579.
58. Bik, E.M., Eckburg, P.B., Gill, S.R., Nelson, K.E., Purdom, E.A., Francois, F., et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A 103 (2006), 732–737.
59. Iizasa, H., Ishihara, S., Richardo, T., Kanehiro, Y., Yoshiyama, H., Dysbiotic infection in the stomach. World J Gastroenterol 21 (2015), 11450–11457.
60. Aviles-Jimenez, F., Vazquez-Jimenez, F., Medrano-Guzman, R., Mantilla, A., Torres, J., Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci Rep, 4, 2014, 4202.
61. Wang, J., Zhao, L., Yan, H., Che, J., Huihui, L., Jun, W., et al. A meta-analysis and systematic review on the association between human papillomavirus (types 16 and 18) infection and esophageal cancer worldwide. PLoS One, 11, 2016, e0159140.
62. Dias-Jácome, E., Libânio, D., Borges-Canha, M., Galaghar, A., Pimentel-Nunes, P., Gastric microbiota and carcinogenesis: the role of non-Helicobacter pylori bacteria – a systematic review. Rev Esp Enferm Dig 108 (2016), 530–540.
63. Mohiuddin, M.K., Chava, S., Upendrum, P., Latha, M., Zubeda, S., Kumar, A., et al. Role of human papilloma virus infection and altered methylation of specific genes in esophageal cancer. Asian Pac J Cancer Prev 14 (2013), 4187–4193.
64. Ludmir, E.B., Stephens, S.J., Palta, M., Willett, C.G., Czito, B.G., Human papillomavirus tumor infection in esophageal squamous cell carcinoma. J Gastrointest Oncol 6 (2015), 287–295.
65. Xu, W., Liu, Z., Bao, Q., Qian, Z., Viruses, other pathogenic microorganisms and esophageal cancer. Gastrointest Tumors 2 (2015), 2–13.
66. Xie, F.J., Zhang, Y.P., Zheng, Q.Q., Jin, H.C., Wang, F.L., Chen, M., et al. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol 19 (2013), 6098–6107.
67. Runge, T.M., Abrams, J.A., Shaheen, N.J., Epidemiology of Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 44 (2015), 203–231.
68. Neto, A.G., Whitaker, A., Pei, Z., Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma. Semin Oncol 43 (2016), 86–96.
69. Amir, I., Konikoff, F.M., Oppenheim, M., Gophna, U., Half, E.E., Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. Environ Microbiol 16 (2014), 2905–2914.
70. Hu, Q., Sun, T.T., Hong, J., Fang, J.Y., Xiong, H., Meltzer, S.J., Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a systematic review and meta-analysis. PLoS One, 12, 2017, e0169691.
71. Nasrollahzadeh, D., Malekzadeh, R., Ploner, A., Shakeri, R., Sotoudeh, M., Fahimi, S., et al. Variations of gastric corpus microbiota are associated with early esophageal squamous cell carcinoma and squamous dysplasia. Sci Rep, 5, 2015, 8820.
72. Patel, T., Bhattacharya, P., Das, S., Gut microbiota: an indicator to gastrointestinal tract diseases. J Gastrointest Cancer 47 (2016), 232–238.
73. Yang, L., Lu, X., Nossa, C.W., Francois, F., Peek, R.M., Pei, Z., Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 137 (2009), 588–597.
74. Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56 (2007), 1761–1772.
75. Yang, L., Francois, F., Pei, Z., Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res 18 (2012), 2138–2144.
76. Lee, S.J., Park, H., Chang, J.H., Conklin, J.L., Generation of nitric oxide in the opossum lower esophageal sphincter during physiological experimentation. Yonsei Med J 47 (2006), 223–229.
77. Chiu, W.T., Lin, Y.L., Chou, C.W., Chen, R.M., Propofol inhibits lipoteichoic acid-induced iNOS gene expression in macrophages possibly through downregulation of toll-like receptor 2-mediated activation of Raf-MEK1/2-ERK1/2-IKK-NFkappaB. Chem Biol Interact 181 (2009), 430–439.
78. Kuo, W.T., Lee, T.C., Yang, H.Y., Chen, C.Y., Au, Y.C., Lu, Y.Z., et al. LPS receptor subunits have antagonistic roles in epithelial apoptosis and colonic carcinogenesis. Cell Death Differ 22 (2015), 1590–1604.
79. Su, S.C., Hua, K.F., Lee, H., Chao, L.K., Tan, S.K., Yang, S.F., et al. LTA and LPS mediated activation of protein kinases in the regulation of inflammatory cytokines expression in macrophages. Clin Chim Acta 374 (2006), 106–115.
80. Wells, J.E., Hylemon, P.B., Identification and characterization of a bile acid 7alpha-dehydroxylation operon in Clostridium sp. strain TO-931, a highly active 7alpha-dehydroxylating strain isolated from human feces. Appl Environ Microbiol 66 (2000), 1107–1113.
81. Canani, R.B., Costanzo, M.D., Leone, L., Pedata, M., Meli, R., Calignano, A., Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 17 (2011), 1519–1528.
82. Louis, P., Flint, H.J., Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 294 (2009), 1–8.
83. Richards, J.L., Yap, Y.A., McLeod, K.H., Mackay, C.R., Mariño, E., Dietary metabolites and the gut microbiota: an alternative approach to control inflammatory and autoimmune diseases. Clin Transl Immunol, 5, 2016, e82.
84. Elangovan, S., Pathania, R., Ramachandran, S., Ananth, S., Padia, R.N., Lan, L., et al. The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival. Cancer Res 74 (2014), 1166–1178.
85. Singh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H., et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40 (2014), 128–139.
86. Bardhan, K., Paschall, A.V., Yang, D., Chen, M.R., Simon, P.S., Bhutia, Y.D., et al. IFNγ induces DNA methylation-silenced GPR109A expression via pSTAT1/p300 and H3K18 acetylation in colon cancer. Cancer Immunol Res 3 (2015), 795–805.
87. Pudlo, N.A., Urs, K., Kumar, S.S., German, J.B., Mills, D.A., Martens, E.C., Symbiotic human gut bacteria with variable metabolic priorities for host mucosal glycans. MBio, 6, 2015 e01282–15.
88. Nepelska, M., Cultrone, A., Béguet-Crespel, F., Le Roux, K., Doré J., Arulampalam, V., et al. Butyrate produced by commensal bacteria potentiates phorbol esters induced AP-1 response in human intestinal epithelial cells. PLoS One, 7, 2012, e52869.
89. González-Sarrías, A., Giménez-Bastida, J.A., Núñez-Sánchez, M., Larrosa, M., García-Conesa, M.T., Tomás-Barberán, F.A., et al. Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells. Eur J Nutr 53 (2014), 853–864.
90. Sharma, M., Li, L., Celver, J., Killian, C., Kovoor, A., Seeram, N.P., Effects of fruit ellagitannin extracts, ellagic acid, and their colonic metabolite, urolithin A, on Wnt signaling. J Agric Food Chem 58 (2010), 3965–3969.
91. Saleh, M., Trinchieri, G., Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol 11 (2011), 9–20.
92. Tomasello, G., Tralongo, P., Damiani, P., Sinagra, E., Di Trapani, B., Zeenny, M.N., et al. Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes. World J Gastroenterol 20 (2014), 18121–18130.
93. Sokol, H., Leducq, V., Aschard, H., Pham, H.P., Jegou, S., Landman, C., et al. Fungal microbiota dysbiosis in IBD. Gut 66 (2017), 1039–1048.
94. Prindiville, T.P., Sheikh, R.A., Cohen, S.H., Tang, Y.J., Cantrell, M.C., Silva, J., Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease. Emerg Infect Dis 6 (2000), 171–174.
95. Basset, C., Holton, J., Bazeos, A., Vaira, D., Bloom, S., Are Helicobacter species and enterotoxigenic Bacteroides fragilis involved in inflammatory bowel disease?. Dig Dis Sci 49 (2004), 1425–1432.
96. Jurjus, A., Eid, A., Al Kattar, S., Zeenny, M.N., Gerges-Geagea, A., Haydar, H., et al. Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: the links. BBA Clin 5 (2016), 16–24.
97. Ou, B., Zhao, J., Guan, S., Lu, A., Survival of colorectal cancer in patients with or without inflammatory bowel disease: a meta-analysis. Dig Dis Sci 61 (2016), 881–889.
98. Wu, S., Powell, J., Mathioudakis, N., Kane, S., Fernandez, E., Sears, C.L., Bacteroides fragilis enterotoxin induces intestinal epithelial cell secretion of interleukin-8 through mitogen-activated protein kinases and a tyrosine kinase-regulated nuclear factor-kappaB pathway. Infect Immun 72 (2004), 5832–5839.
99. Wu, S., Rhee, K.J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.R., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15 (2009), 1016–1022.
100. Kim, J.M., Lee, J.Y., Yoon, Y.M., Oh, Y.K., Kang, J.S., Kim, Y.J., et al. Bacteroides fragilis enterotoxin induces cyclooxygenase-2 and fluid secretion in intestinal epithelial cells through NF-kappaB activation. Eur J Immunol 36 (2006), 2446–2456.
101. Wu, S., Morin, P.J., Maouyo, D., Sears, C.L., Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology 124 (2003), 392–400.
102. Peters, B.A., Dominianni, C., Shapiro, J.A., Church, T.R., Wu, J., Miller, G., et al. The gut microbiota in conventional and serrated precursors of colorectal cancer. Microbiome, 4, 2016, 69.
103. Dejea, C.M., Sears, C.L., Do biofilms confer a pro-carcinogenic state?. Gut Microbes 7 (2016), 54–57.
104. Coleman, O.I., Nunes, T., Role of the microbiota in colorectal cancer: updates on microbial associations and therapeutic implications. Biores Open Access 5 (2016), 279–288.
105. Gagnière, J., Raisch, J., Veziant, J., Barnich, N., Bonnet, R., Buc, E., et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 22 (2016), 501–518.
106. Shen, X.J., Rawls, J.F., Randall, T., Burcal, L., Mpande, C.N., Jenkins, N., et al. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes 1 (2010), 138–147.
107. Castellarin, M., Warren, R.L., Freeman, J.D., Dreolini, L., Krzywinski, M., Strauss, J., et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22 (2012), 299–306.
108. Rubinstein, M.R., Wang, X., Liu, W., Hao, Y., Cai, G., Han, Y.W., Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14 (2013), 195–206.
109. Kostic, A.D., Chun, E., Robertson, L., Glickman, J.N., Gallini, C.A., Michaud, M., et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14 (2013), 207–215.
110. Repass, J., Maherali, N., Owen, K., Biology, R.P.C., Biology, R.P.C., Registered report: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Elife, 5, 2016, e10012.
111. Lightfoot, Y.L., Mohamadzadeh, M., Tailoring gut immune responses with lipoteichoic acid-deficient Lactobacillus acidophilus. Front Immunol, 4, 2013, 25.
112. Fukata, M., Abreu, M.T., TLR4 signalling in the intestine in health and disease. Biochem Soc Trans 35 (2007), 1473–1478.
113. Rakoff-Nahoum, S., Medzhitov, R., Innate immune recognition of the indigenous microbial flora. Mucosal Immunol 1 (2008), S10–S14.
114. Parlato, M., Yeretssian, G., NOD-like receptors in intestinal homeostasis and epithelial tissue repair. Int J Mol Sci 15 (2014), 9594–9627.
115. Asquith, M., Powrie, F., An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer. J Exp Med 207 (2010), 1573–1577.
116. Fukata, M., Abreu, M.T., Microflora in colorectal cancer: a friend to fear. Nat Med 16 (2010), 639–641.
117. An, J., Ha, E.M., Combination therapy of Lactobacillus plantarum supernatant and 5-fluouracil increases chemosensitivity in colorectal cancer cells. J Microbiol Biotechnol 26 (2016), 1490–1503.
118. Beutler, B., Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430 (2004), 257–263.
119. Moossavi, S., Rezaei, N., Toll-like receptor signalling and their therapeutic targeting in colorectal cancer. Int Immunopharmacol 16 (2013), 199–209.
120. Lascorz, J., Hemminki, K., Försti, A., Systematic enrichment analysis of gene expression profiling studies identifies consensus pathways implicated in colorectal cancer development. J Carcinog, 10, 2011, 7.
121. Chen, G.Y., Shaw, M.H., Redondo, G., Núñez, G., The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res 68 (2008), 10060–10067.
122. Arthur, J.C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J.M., Fan, T.J., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338 (2012), 120–123.
123. Nesić D., Hsu, Y., Stebbins, C.E., Assembly and function of a bacterial genotoxin. Nature 429 (2004), 429–433.
124. Cuevas-Ramos, G., Petit, C.R., Marcq, I., Boury, M., Oswald, E., Nougayrède, J.P., Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A 107 (2010), 11537–11542.
125. De Rycke, J., Oswald, E., Cytolethal distending toxin (CDT): a bacterial weapon to control host cell proliferation?. FEMS Microbiol Lett 203 (2001), 141–148.
126. Lara-Tejero, M., Galán, J.E., Cytolethal distending toxin: limited damage as a strategy to modulate cellular functions. Trends Microbiol 10 (2002), 147–152.
127. Smith, J.L., Bayles, D.O., The contribution of cytolethal distending toxin to bacterial pathogenesis. Crit Rev Microbiol 32 (2006), 227–248.
128. Yamtich, J., Nemec, A.A., Keh, A., Sweasy, J.B., A germline polymorphism of DNA polymerase beta induces genomic instability and cellular transformation. PLoS Genet, 8, 2012, e1003052.
129. Huycke, M.M., Abrams, V., Moore, D.R., Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. Carcinogenesis 23 (2002), 529–536.
130. Wang, X., Huycke, M.M., Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells. Gastroenterology 132 (2007), 551–561.
131. Klimesova, K., Kverka, M., Zakostelska, Z., Hudcovic, T., Hrncir, T., Stepankova, R., et al. Altered gut microbiota promotes colitis-associated cancer in IL-1 receptor-associated kinase M-deficient mice. Inflamm Bowel Dis 19 (2013), 1266–1277.
132. Ray, D., Kidane, D., Gut microbiota imbalance and base excision repair dynamics in colon cancer. J Cancer 7 (2016), 1421–1430.
133. Brevik, A., Joshi, A.D., Corral, R., Onland-Moret, N.C., Siegmund, K.D., Le Marchand, L., et al. Polymorphisms in base excision repair genes as colorectal cancer risk factors and modifiers of the effect of diets high in red meat. Cancer Epidemiol Biomarkers Prev 19 (2010), 3167–3173.
134. Ogino, S., Lochhead, P., Giovannucci, E., Meyerhardt, J.A., Fuchs, C.S., Chan, A.T., Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene 33 (2014), 2949–2955.
135. Umar, S., Enteric pathogens and cellular transformation: bridging the gaps. Oncotarget 5 (2014), 6573–6575.
136. Thiery, J.P., Acloque, H., Huang, R.Y., Nieto, M.A., Epithelial-mesenchymal transitions in development and disease. Cell 139 (2009), 871–890.
137. Chandrakesan, P., Roy, B., Jakkula, L.U., Ahmed, I., Ramamoorthy, P., Tawfik, O., et al. Utility of a bacterial infection model to study epithelial-mesenchymal transition, mesenchymal-epithelial transition or tumorigenesis. Oncogene 33 (2014), 2639–2654.
138. Li, C.W., Xia, W., Huo, L., Lim, S.O., Wu, Y., Hsu, J.L., et al. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res 72 (2012), 1290–1300.
139. Mladinich, M., Ruan, D., Chan, C.H., Tackling cancer stem cells via inhibition of EMT transcription factors. Stem Cells Int, 2016, 2016, 5285892.
140. Ohtani, N., Microbiome and cancer. Semin Immunopathol 37 (2015), 65–72.
141. Schinzari, V., Barnaba, V., Piconese, S., Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clin Microbiol Infect 21 (2015), 969–974.
142. Wong, C.R., Nguyen, M.H., Lim, J.K., Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. World J Gastroenterol 22 (2016), 8294–8303.
143. French, S.W., Epigenetic events in liver cancer resulting from alcoholic liver disease. Alcohol Res 35 (2013), 57–67.
144. Yu, J., Marsh, S., Hu, J., Feng, W., Wu, C., The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterol Res Pract, 2016, 2016, 2862173.
145. Aqel, B., DiBaise, J.K., Role of the gut microbiome in nonalcoholic fatty liver disease. Nutr Clin Pract 30 (2015), 780–786.
146. Grąt, M., Wronka, K.M., Krasnodębski, M., Masior, Ł., Lewandowski, Z., Kosińska, I., et al. Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis. Transplant Proc 48 (2016), 1687–1691.
147. Chng, K.R., Chan, S.H., Ng, A.H., Li, C., Jusakul, A., Bertrand, D., et al. Tissue microbiome profiling identifies an enrichment of specific enteric bacteria in Opisthorchis viverrini associated cholangiocarcinoma. EBioMedicine 8 (2016), 195–202.
148. Roubaud Baudron, C., Franceschi, F., Salles, N., Gasbarrini, A., Extragastric diseases and Helicobacter pylori. Helicobacter 18 (2013), 44–51.
149. Pellicano, R., Ménard, A., Rizzetto, M., Mégraud, F., Helicobacter species and liver diseases: association or causation?. Lancet Infect Dis 8 (2008), 254–260.
150. de Magalhães Queiroz, D.M., Santos, A., Isolation of a Helicobacter strain from the human liver. Gastroenterology 121 (2001), 1023–1024.
151. Tu, Q.V., Okoli, A.S., Kovach, Z., Mendz, G.L., Hepatocellular carcinoma: prevalence and molecular pathogenesis of Helicobacter spp. Future Microbiol 4 (2009), 1283–1301.
152. Tsuneyama, K., Harada, K., Kono, N., Hiramatsu, K., Zen, Y., Sudo, Y., et al. Scavenger cells with gram-positive bacterial lipoteichoic acid infiltrate around the damaged interlobular bile ducts of primary biliary cirrhosis. J Hepatol 35 (2001), 156–163.
153. Dore, M.P., Realdi, G., Mura, D., Graham, D.Y., Sepulveda, A.R., Helicobacter infection in patients with HCV-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Dig Dis Sci 47 (2002), 1638–1643.
154. Queiroz, D.M., Rocha, A.M., Rocha, G.A., Cinque, S.M., Oliveira, A.G., Godoy, A., et al. Association between Helicobacter pylori infection and cirrhosis in patients with chronic hepatitis C virus. Dig Dis Sci 51 (2006), 370–373.
155. Liu, X., Liang, J., Li, G., Lipopolysaccharide promotes adhesion and invasion of hepatoma cell lines HepG2 and HepG2.2.15. Mol Biol Rep 37 (2010), 2235–2239.
156. Fox, J.G., Feng, Y., Theve, E.J., Raczynski, A.R., Fiala, J.L., Doernte, A.L., et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 59 (2010), 88–97.
157. Zhou, D., Wang, J.D., Weng, M.Z., Zhang, Y., Wang, X.F., Gong, W., et al. Infections of Helicobacter spp. in the biliary system are associated with biliary tract cancer: a meta-analysis. Eur J Gastroenterol Hepatol 25 (2013), 447–454.
158. Maeda, S., Kamata, H., Luo, J.L., Leffert, H., Karin, M., IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005), 977–990.
159. Dapito, D.H., Mencin, A., Gwak, G.Y., Pradere, J.P., Jang, M.K., Mederacke, I., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21 (2012), 504–516.
160. Szabo, G., Dolganiuc, A., Mandrekar, P., Pattern recognition receptors: a contemporary view on liver diseases. Hepatology 44 (2006), 287–298.
161. Yu, L.X., Yan, H.X., Liu, Q., Yang, W., Wu, H.P., Dong, W., et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 52 (2010), 1322–1333.
162. Payne, C.M., Weber, C., Crowley-Skillicorn, C., Dvorak, K., Bernstein, H., Bernstein, C., et al. Deoxycholate induces mitochondrial oxidative stress and activates NF-kappaB through multiple mechanisms in HCT-116 colon epithelial cells. Carcinogenesis 28 (2007), 215–222.
163. Ridlon, J.M., Kang, D.J., Hylemon, P.B., Bajaj, J.S., Bile acids and the gut microbiome. Curr Opin Gastroenterol 30 (2014), 332–338.
164. Yoshimoto, S., Loo, T.M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499 (2013), 97–101.
165. Hara, E., Relationship between obesity, gut microbiome and hepatocellular carcinoma development. Dig Dis 33 (2015), 346–350.
166. Carvalho, B.M., Saad, M.J., Influence of gut microbiota on subclinical inflammation and insulin resistance. Mediators Inflamm, 2013, 2013, 986734.
167. Turati, F., Talamini, R., Pelucchi, C., Polesel, J., Franceschi, S., Crispo, A., et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer 108 (2013), 222–228.
168. Borena, W., Strohmaier, S., Lukanova, A., Bjørge, T., Lindkvist, B., Hallmans, G., et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer 131 (2012), 193–200.
169. Park, E.J., Lee, J.H., Yu, G.Y., He, G., Ali, S.R., Holzer, R.G., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140 (2010), 197–208.
170. Wang, C., Li, J., Pathogenic microorganisms and pancreatic cancer. Gastrointest Tumors 2 (2015), 41–47.
171. Michaud, D.S., Izard, J., Microbiota, oral microbiome, and pancreatic cancer. Cancer J 20 (2014), 203–206.
172. Zambirinis, C.P., Pushalkar, S., Saxena, D., Miller, G., Pancreatic cancer, inflammation, and microbiome. Cancer J 20 (2014), 195–202.
173. Yu, H., Pardoll, D., Jove, R., STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9 (2009), 798–809.
174. Rabelo-Gonçalves, E.M., Roesler, B.M., Zeitune, J.M., Extragastric manifestations of Helicobacter pylori infection: possible role of bacterium in liver and pancreas diseases. World J Hepatol 7 (2015), 2968–2979.
175. Bulajic, M., Panic, N., Löhr, J.M., Helicobacter pylori and pancreatic diseases. World J Gastrointest Pathophysiol 5 (2014), 380–383.
176. Goni, E., Franceschi, F., Helicobacter pylori and extragastric diseases. Helicobacter 21 (2016), 45–48.
177. Warzecha, Z., Dembiński, A., Ceranowicz, P., Dembiński, M., Sendur, R., Pawlik, W.W., et al. Deleterious effect of Helicobacter pylori infection on the course of acute pancreatitis in rats. Pancreatology 2 (2002), 386–395.
178. Niemann, T., Larsen, S., Mouritsen, E.A., Thorsgaard, N., Helicobacter pylori infection in patients with chronic pancreatitis and duodenal ulcer. Scand J Gastroenterol 32 (1997), 1201–1203.
179. Manes, G., Dominguez-Muñoz, J.E., Hackelsberger, A., Leodolter, A., Rössner, A., Malfertheiner, P., Prevalence of Helicobacter pylori infection and gastric mucosal abnormalities in chronic pancreatitis. Am J Gastroenterol 93 (1998), 1097–1100.
180. Kountouras, J., Zavos, C., Chatzopoulos, D., A concept on the role of Helicobacter pylori infection in autoimmune pancreatitis. J Cell Mol Med 9 (2005), 196–207.
181. Manes, G., Balzano, A., Vaira, D., Helicobacter pylori and pancreatic disease. JOP 4 (2003), 111–116.
182. Takayama, S., Takahashi, H., Matsuo, Y., Okada, Y., Manabe, T., Effects of Helicobacter pylori infection on human pancreatic cancer cell line. Hepatogastroenterology 54 (2007), 2387–2391.
183. di Magliano, M.P., Logsdon, C.D., Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 144 (2013), 1220–1229.
184. Huang, H., Daniluk, J., Liu, Y., Chu, J., Li, Z., Ji, B., et al. Oncogenic K-Ras requires activation for enhanced activity. Oncogene 33 (2014), 532–535.
185. Daniluk, J., Liu, Y., Deng, D., Chu, J., Huang, H., Gaiser, S., et al. An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 122 (2012), 1519–1528.
186. Fukuda, A., Wang, S.C., Morris, J.P., Folias, A.E., Liou, A., Kim, G.E., et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19 (2011), 441–455.
187. Lesina, M., Kurkowski, M.U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19 (2011), 456–469.
188. Wörmann, S.M., Diakopoulos, K.N., Lesina, M., Algül, H., The immune network in pancreatic cancer development and progression. Oncogene 33 (2014), 2956–2967.
189. Sharif, R., Dawra, R., Wasiluk, K., Phillips, P., Dudeja, V., Kurt-Jones, E., et al. Impact of toll-like receptor 4 on the severity of acute pancreatitis and pancreatitis-associated lung injury in mice. Gut 58 (2009), 813–819.
190. Ochi, A., Graffeo, C.S., Zambirinis, C.P., Rehman, A., Hackman, M., Fallon, N., et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest 122 (2012), 4118–4129.
191. Ochi, A., Nguyen, A.H., Bedrosian, A.S., Mushlin, H.M., Zarbakhsh, S., Barilla, R., et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med 209 (2012), 1671–1687.
192. Ding, S.P., Li, J.C., Jin, C., A mouse model of severe acute pancreatitis induced with caerulein and lipopolysaccharide. World J Gastroenterol 9 (2003), 584–589.
193. Alam, M.S., Gaida, M.M., Bergmann, F., Lasitschka, F., Giese, T., Giese, N.A., et al. Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression. Nat Med 21 (2015), 1337–1343.
194. Gaida, M.M., Mayer, C., Dapunt, U., Stegmaier, S., Schirmacher, P., Wabnitz, G.H., et al. Expression of the bitter receptor T2R38 in pancreatic cancer: localization in lipid droplets and activation by a bacteria-derived quorum-sensing molecule. Oncotarget 7 (2016), 12623–12632.
195. Mitsuhashi, K., Nosho, K., Sukawa, Y., Matsunaga, Y., Ito, M., Kurihara, H., et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 6 (2015), 7209–7220.
196. Pandey, K.R., Naik, S.R., Vakil, B.V., Probiotics, prebiotics and synbiotics- a review. J Food Sci Technol 52 (2015), 7577–7587.
197. Greiner, A.K., Papineni, R.V., Umar, S., Chemoprevention in gastrointestinal physiology and disease. Natural products and microbiome. Am J Physiol Gastrointest Liver Physiol 307 (2014), G1–G15.
198. Power, K.A., Lepp, D., Zarepoor, L., Monk, J.M., Wu, W., Tsao, R., et al. Dietary flaxseed modulates the colonic microenvironment in healthy C57Bl/6 male mice which may alter susceptibility to gut-associated diseases. J Nutr Biochem 28 (2016), 61–69.
199. Pattananandecha, T., Sirilun, S., Duangjitcharoen, Y., Sivamaruthi, B.S., Suwannalert, P., Peerajan, S., et al. Hydrolysed inulin alleviates the azoxymethane-induced preneoplastic aberrant crypt foci by altering selected intestinal microbiota in Sprague-Dawley rats. Pharm Biol 54 (2016), 1596–1605.
200. Wang, P., Chen, H., Zhu, Y., McBride, J., Fu, J., Sang, S., Oat avenanthramide-C (2c) is biotransformed by mice and the human microbiota into bioactive metabolites. J Nutr 145 (2015), 239–245.
201. Nuñez-Sánchez, M.A., García-Villalba, R., Monedero-Saiz, T., García-Talavera, N.V., Gómez-Sánchez, M.B., Sánchez-Álvarez, C., et al. Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients. Mol Nutr Food Res 58 (2014), 1199–1211.
202. Allsopp, P., Possemiers, S., Campbell, D., Gill, C., Rowland, I., A comparison of the anticancer properties of isoxanthohumol and 8-prenylnaringenin using in vitro models of colon cancer. Biofactors 39 (2013), 441–447.
203. Higashimura, Y., Naito, Y., Takagi, T., Uchiyama, K., Mizushima, K., Ushiroda, C., et al. Protective effect of agaro-oligosaccharides on gut dysbiosis and colon tumorigenesis in high-fat diet-fed mice. Am J Physiol Gastrointest Liver Physiol 310 (2016), G367–G375.
204. Li, F., Yang, X.W., Krausz, K.W., Nichols, R.G., Xu, W., Patterson, A.D., et al. Modulation of colon cancer by nutmeg. J Proteome Res 14 (2015), 1937–1946.
205. Schlörmann, W., Birringer, M., Lochner, A., Lorkowski, S., Richter, I., Rohrer, C., et al. In vitro fermentation of nuts results in the formation of butyrate and c9, t11 conjugated linoleic acid as chemopreventive metabolites. Eur J Nutr 55 (2016), 2063–2073.
206. Miene, C., Weise, A., Glei, M., Impact of polyphenol metabolites produced by colonic microbiota on expression of COX-2 and GSTT2 in human colon cells (LT97). Nutr Cancer 63 (2011), 653–662.
207. Piazzi, G., D'Argenio, G., Prossomariti, A., Lembo, V., Mazzone, G., Candela, M., et al. Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota. Int J Cancer 135 (2014), 2004–2013.
208. Winkels, R.M., Heine-Bröring, R.C., van Zutphen, M., van Harten-Gerritsen, S., Kok, D.E., van Duijnhoven, F.J., et al. The COLON study: colorectal cancer: longitudinal, observational study on nutritional and lifestyle factors that may influence colorectal tumour recurrence, survival and quality of life. BMC Cancer, 14, 2014, 374.
209. Costabile, A., Fava, F., Röytiö H., Forssten, S.D., Olli, K., Klievink, J., et al. Impact of polydextrose on the faecal microbiota: a double-blind, crossover, placebo-controlled feeding study in healthy human subjects. Br J Nutr 108 (2012), 471–481.
210. Eid, N., Osmanova, H., Natchez, C., Walton, G., Costabile, A., Gibson, G., et al. Impact of palm date consumption on microbiota growth and large intestinal health: a randomised, controlled, cross-over, human intervention study. Br J Nutr 114 (2015), 1226–1236.
211. Zhu, Y., Michelle Luo, T., Jobin, C., Young, H.A., Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett 309 (2011), 119–127.
212. Tojo, R., Suárez, A., Clemente, M.G., de los Reyes-Gavilán, C.G., Margolles, A., Gueimonde, M., et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol 20 (2014), 15163–15176.
213. Ambalam, P., Raman, M., Purama, R.K., Doble, M., Probiotics, prebiotics and colorectal cancer prevention. Best Pract Res Clin Gastroenterol 30 (2016), 119–131.
214. Gianotti, L., Morelli, L., Galbiati, F., Rocchetti, S., Coppola, S., Beneduce, A., et al. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol 16 (2010), 167–175.
215. Zhang, M., Fan, X., Fang, B., Zhu, C., Zhu, J., Ren, F., Effects of Lactobacillus salivarius Ren on cancer prevention and intestinal microbiota in 1, 2-dimethylhydrazine-induced rat model. J Microbiol 53 (2015), 398–405.
216. Kuugbee, E.D., Shang, X., Gamallat, Y., Bamba, D., Awadasseid, A., Suliman, M.A., et al. Structural change in microbiota by a probiotic cocktail enhances the gut barrier and reduces cancer via TLR2 signaling in a rat model of colon cancer. Dig Dis Sci 61 (2016), 2908–2920.
217. Li, J., Sung, C.Y., Lee, N., Ni, Y., Pihlajamäki, J., Panagiotou, G., et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A 113 (2016), E1306–E1315.
218. Jakobsson, H.E., Jernberg, C., Andersson, A.F., Sjölund-Karlsson, M., Jansson, J.K., Engstrand, L., Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One, 5, 2010, e9836.
219. Oh, B., Kim, B.S., Kim, J.W., Kim, J.S., Koh, S.J., Kim, B.G., et al. The effect of probiotics on gut microbiota during the Helicobacter pylori eradication: randomized controlled trial. Helicobacter 21 (2016), 165–174.
220. Motoori, M., Yano, M., Miyata, H., Sugimura, K., Saito, T., Omori, T., et al. Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. Clin Nutr 36 (2017), 93–99.
221. Abreu, M.T., Peek, R.M., Gastrointestinal malignancy and the microbiome. Gastroenterology 146 (2014), 1534–1546.
222. Couturier-Maillard, A., Secher, T., Rehman, A., Normand, S., De Arcangelis, A., Haesler, R., et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest 123 (2013), 700–711.
223. Pestell, R.G., Rizvanov, A.A., Antibiotics for cancer therapy. Oncotarget 6 (2015), 2587–2588.
224. Zackular, J.P., Baxter, N.T., Chen, G.Y., Schloss, P.D., Manipulation of the gut microbiota reveals role in colon tumorigenesis. mSphere 1 (2015), e00001–e00015.
225. DeStefano Shields, C.E., Van Meerbeke, S.W., Housseau, F., Wang, H., Huso, D.L., Casero, R.A., et al. Reduction of murine colon tumorigenesis driven by enterotoxigenic Bacteroides fragilis using Cefoxitin Treatment. J Infect Dis 214 (2016), 122–129.
226. Boursi, B., Mamtani, R., Haynes, K., Yang, Y.X., Recurrent antibiotic exposure may promote cancer formation–another step in understanding the role of the human microbiota?. Eur J Cancer 51 (2015), 2655–2664.
227. Yang, B., Hagberg, K.W., Chen, J., Sahasrabuddhe, V.V., Graubard, B.I., Jick, S., et al. Associations of antibiotic use with risk of primary liver cancer in the clinical practice research datalink. Br J Cancer 115 (2016), 85–89.
228. Montrose, D.C., Zhou, X.K., McNally, E.M., Sue, E., Yantiss, R.K., Gross, S.S., et al. Celecoxib alters the intestinal microbiota and metabolome in association with reducing polyp burden. Cancer Prev Res (Phila) 9 (2016), 721–731.
229. Wallace, B.D., Wang, H., Lane, K.T., Scott, J.E., Orans, J., Koo, J.S., et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330 (2010), 831–835.
230. Lin, X.B., Dieleman, L.A., Ketabi, A., Bibova, I., Sawyer, M.B., Xue, H., et al. Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats. PLoS One, 7, 2012, e39764.
231. González-Sarrías, A., Tomé-Carneiro, J., Bellesia, A., Tomás-Barberán, F.A., Espín, J.C., The ellagic acid-derived gut microbiota metabolite, urolithin A, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells. Food Funct 6 (2015), 1460–1469.
232. Leslie, M., MICROBIOME. Microbes aid cancer drugs. Science 350 (2015), 614–615.
233. Vétizou, M., Pitt, J.M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350 (2015), 1079–1084.
234. Sivan, A., Corrales, L., Hubert, N., Williams, J.B., Aquino-Michaels, K., Earley, Z.M., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350 (2015), 1084–1089.
235. Wang, C.Z., Zhang, C.F., Chen, L., Anderson, S., Lu, F., Yuan, C.S., Colon cancer chemopreventive effects of baicalein, an active enteric microbiome metabolite from baicalin. Int J Oncol 47 (2015), 1749–1758.
236. McFadden, R.M., Larmonier, C.B., Shehab, K.W., Midura-Kiela, M., Ramalingam, R., Harrison, C.A., et al. The role of curcumin in modulating colonic microbiota during colitis and colon cancer prevention. Inflamm Bowel Dis 21 (2015), 2483–2494.
237. Nelson, K.M., Dahlin, J.L., Bisson, J., Graham, J., Pauli, G.F., Walters, M.A., The essential medicinal chemistry of curcumin. J Med Chem 60 (2017), 1620–1637.
238. Lam, W., Bussom, S., Guan, F., Jiang, Z., Zhang, W., Gullen, E.A., et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med, 2, 2010, 45ra59.
239. Lam, W., Jiang, Z., Guan, F., Hu, R., Liu, S.H., Chu, E., et al. The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018). BMC Complement Altern Med, 14, 2014, 490.
240. Kummar, S., Copur, M.S., Rose, M., Wadler, S., Stephenson, J., O'Rourke, M., et al. A phase I study of the Chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 10 (2011), 85–96.
241. Wang, E., Bussom, S., Chen, J., Quinn, C., Bedognetti, D., Lam, W., et al. Interaction of a traditional Chinese medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC Med Genomics, 4, 2011, 38.
242. Zhang, W., Saif, M.W., Dutschman, G.E., Li, X., Lam, W., Bussom, S., et al. Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). J Chromatogr A 1217 (2010), 5785–5793.
243. Farrell, M.P., Kummar, S., Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2 (2003), 253–256.
244. Mima, K., Nishihara, R., Qian, Z.R., Cao, Y., Sukawa, Y., Nowak, J.A., et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 65 (2016), 1974–1980.